239 related articles for article (PubMed ID: 32003251)
1. MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
2. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
3. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
4. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
5. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
Tokgun O; Tokgun PE; Inci K; Akca H
Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
[TBL] [Abstract][Full Text] [Related]
6. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
7.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract][Full Text] [Related]
8. Family matters: How MYC family oncogenes impact small cell lung cancer.
Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
[TBL] [Abstract][Full Text] [Related]
9. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
[TBL] [Abstract][Full Text] [Related]
10. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
[TBL] [Abstract][Full Text] [Related]
11. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
12. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
[TBL] [Abstract][Full Text] [Related]
13. C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target.
Chanvorachote P; Sriratanasak N; Nonpanya N
Anticancer Res; 2020 Feb; 40(2):609-618. PubMed ID: 32014901
[TBL] [Abstract][Full Text] [Related]
14. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.
Fukazawa T; Maeda Y; Matsuoka J; Yamatsuji T; Shigemitsu K; Morita I; Faiola F; Durbin ML; Soucek L; Naomoto Y
Anticancer Res; 2010 Oct; 30(10):4193-200. PubMed ID: 21036740
[TBL] [Abstract][Full Text] [Related]
16. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
17. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain and hedgehog pathway targets in small cell lung cancer.
Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
[TBL] [Abstract][Full Text] [Related]
19. A big step for MYC-targeted therapies.
Atibalentja DF; Deutzmann A; Felsher DW
Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
[TBL] [Abstract][Full Text] [Related]
20. Alternative approaches to target Myc for cancer treatment.
Wang C; Zhang J; Yin J; Gan Y; Xu S; Gu Y; Huang W
Signal Transduct Target Ther; 2021 Mar; 6(1):117. PubMed ID: 33692331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
